Agenus Inc. (AGEN)
NASDAQ: AGEN · Real-Time Price · USD
3.750
+0.050 (1.35%)
Jan 8, 2026, 4:00 PM EST - Market closed
Agenus Employees
Agenus had 316 employees as of December 31, 2024. The number of employees decreased by 73 or -18.77% compared to the previous year.
Employees
316
Change (1Y)
-73
Growth (1Y)
-18.77%
Revenue / Employee
$338,066
Profits / Employee
-$111,968
Market Cap
127.53M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 316 | -73 | -18.77% |
| Dec 31, 2023 | 389 | -144 | -27.02% |
| Dec 31, 2022 | 533 | 92 | 20.86% |
| Dec 31, 2021 | 441 | 82 | 22.84% |
| Dec 31, 2020 | 359 | 31 | 9.45% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AGEN News
- 16 days ago - Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC - Business Wire
- 5 weeks ago - Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript - Seeking Alpha
- 7 weeks ago - Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL - Business Wire
- 7 weeks ago - Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France's AAC - Business Wire
- 2 months ago - Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances - Business Wire
- 2 months ago - Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report - Business Wire
- 2 months ago - Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025 - Business Wire
- 3 months ago - Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights - Business Wire